Synthetic Cannabinoids: An Overview
Presented By LAUREN PACE, DO
Provided by RiverMend Health Institute
Scroll to the Bottom of this Information to Begin this Course
Release date: March 30, 2017
Valid through: March 30, 2020
Topic: Synthetic Cannabinoid
Media: Recorded/On demand
Estimated Time to Complete Activity: 60 minutes
This CE activity is intended for physicians, psychiatrists, physician assistants, psychologists, and allied mental health advocates.
Synthetic Cannabinoids (SCs) have become widely abused as recreational drugs, and are now known to carry a risk of severe mental and physical health effects. SCs mimic the psychoactive effects of cannabis and have been recognized as drugs of abuse since 2008. However, SCs differ structurally from cannabis, which may explain the emergence of severe psychiatric symptoms following SC ingestion. This presentation will examine catatonia occurring in the context of SC use in two patients with no prior history of psychosis. Pharmacological management in the context of SC induced catatonia will also be discussed, as well as long term sequelae of heavy synthetic cannabinoid use.
Upon completion of this activity, participants should be better able to:
- Discuss the origin and development of synthetic cannabinoids, the prevalence of use, and the legal restrictions now in place.
- Explain the mechanism of action of synthetic cannabinoids and how this illicit substance differs from marijuana.
- Demonstrate the effects of heavy synthetic cannabinoid use through a case presentation, and compare pharmacological treatments available for those who have suffered unintended repercussions after using this substance.
NBCC, National Board of Certified Counselors
RiverMend Health is an NBCC-Approved Continuing Education Provider (ACEP™) and may offer NBCC approved clock hours for events that meet NBCC requirements. The ACEP solely is responsible for all aspects of the program. Provider #6573.
NBCC CE credit Awarded: 1.0
LAUREN PACE, DO
Lauren Pace, DO, is an Addiction Psychiatry fellow at the University of Illinois at Chicago. She currently works with people struggling with addiction at the Jesse Brown VA Medical Center, as well as in outpatient medication management and psychotherapy clinics at UIC. Dr. Pace is a board-certified psychiatrist and plans to continue working in Chicago in the field of addiction psychiatry following completion of her fellowship program in July 2017.
Disclosures of Conflicts of Interest
- No financial relationships relevant to this field of study.
Instructions for Participation and Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must read the learning objectives and faculty disclosures; study the educational activity; and complete the post-test and the evaluation form. If you pass the post-test and complete the evaluation, your certificate will be available immediately for download in PDF format.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player. You will need a PDF viewer such as Adobe Reader to view PDF files.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.